Immunotargeting of Cervical Cancer Cells with the Adaptor CAR T-Cell Platform RevCAR
International Journal of Molecular Sciences · 29.10.2026 · 27 (21) · 9704
DOI: 10.3390/ijms27219704 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.10.2026. Verfasst von Nathalia Jones-Cifuentes und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01307 Dresden, Germany. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Antigens, Neoplasm, Neoplasm Proteins, Receptors, Chimeric Antigen. Die Arbeit nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Academic Exchange Service, Industrial University of Santander, Federal Ministry of Research, Technology and Space.
Abstract (Originalsprache)
The Prostate Stem Cell Antigen (PSCA) is not only overexpressed in prostate cancer (PC) but also in many other tumors, including cervical cancer (CC). The adaptor chimeric antigen receptor (CAR) platform RevCAR can be used for immunotargeting of PSCA-expressing tumor cells. We found that the CC cell line SiHa natively expresses PSCA. The expression was sufficient for redirection of RevCAR T-cells using recently described RevCAR target modules (RevTMs) directed against PSCA. Like almost all PC cell lines, however, SiHa cells also downregulate their PSCA expression in cell culture. To overcome this limitation, we established artificially PSCA-overexpressing SiHa cells. Retargeting of RevCAR T-cells strictly depends on PSCA-directed RevTMs and PSCA-expressing target cells. It leads to (i) upregulation of CD69, Perforin and Granzyme B, (ii) lysis of target cells with EC50 values in the picomolar range, and (iii) cytokine secretion of IFN-γ, TNF-α, GM-CSF and IL-2. Phenotypic analysis shows a prominent increase in memory RevCAR T-cells but only a slight increase in exhausted cells, indicating a low level of tonic signaling of RevCAR T-cells. Together, our data supports an efficient and safe immunotargeting of PSCA-expressing CC cells with the RevCAR technology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01307 Dresden, Germany.
- School of Medicine, Department of Basic Sciences, Universidad Industrial de Santander, Bucaramanga 680002, Colombia.
- Mildred Scheel Early Career Center, Faculty of Medicine Carl Gustav Carus, TUD Dresden University of Technology, 01062 Dresden, Germany.
- German Cancer Consortium (DKTK), Partner Site Dresden, 01062 Dresden, Germany.
- National Center for Tumor Diseases (NCT), NCT/UCC Dresden, A Partnership Between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology & Helmholtz-Zentrum Dresden-Ross…
- Brandenburg Medical School and Faculty of Health Science, Institute for Translational Medicine, 14770 Brandenburg, Germany.
ORCID-Profile: Nathalia Jones-Cifuentes, Claudia Arndt, Alexandra von Jutrzenka-Trzebiatowski, Barbara Seliger, Bladimiro Rincon-Orozco
Förderung
- German Academic Exchange Service
- Industrial University of Santander
- Federal Ministry of Research, Technology and Space
- Mildred Scheel Early Career Center Dresden P2 funded by the German Cancer Aid (Deutsche Krebshilfe)
- Helmholtz Initiative and Networking Fund (Radio-Immunotheranostics (MHELTHERA)
- German Cancer Aid
- Universidad Industrial de Santander
- BMBF, Germany
Zitieren
APA
Jones-Cifuentes, N., Arndt, C., Loureiro, L. R., Berndt, N., von Jutrzenka-Trzebiatowski, A., Feldmann, A., Bachmann, J., Seliger, B., Rincon-Orozco, B., & Bachmann, M. (2026). Immunotargeting of Cervical Cancer Cells with the Adaptor CAR T-Cell Platform RevCAR. International Journal of Molecular Sciences, 27(21), 9704. https://doi.org/10.3390/ijms27219704
Vancouver
Jones-Cifuentes N, Arndt C, Loureiro LR, Berndt N, von Jutrzenka-Trzebiatowski A, Feldmann A, et al. Immunotargeting of Cervical Cancer Cells with the Adaptor CAR T-Cell Platform RevCAR. International Journal of Molecular Sciences. 2026;27(21):9704. doi:10.3390/ijms27219704
BibTeX
@article{JonesCifuentes2026,
author = {Jones-Cifuentes, Nathalia and Arndt, Claudia and Loureiro, Liliana R and Berndt, Nicole and von Jutrzenka-Trzebiatowski, Alexandra and Feldmann, Anja and Bachmann, Jennifer and Seliger, Barbara and Rincon-Orozco, Bladimiro and Bachmann, Michael},
title = {Immunotargeting of Cervical Cancer Cells with the Adaptor CAR T-Cell Platform RevCAR},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9704},
doi = {10.3390/ijms27219704}
}
EUVIMED